$CLYD · BEACON TOPCO, INC.
Beacon Topco filed its Q3 FY2026 10-Q. Net loss attributable to shareholders was $6.1M vs $14.6M a year ago; EPS $(1.34) vs $(3.22). Cash and equivalents fell to $49.2M from $70.5M at Dec 31, 2025. The filing reflects the Barinthus Bio scheme of arrangement completed Sept 9, 2026, and a self-tender offer that repurchased 920,605 shares (~20.28%) for ~$6.1M in October 2026. The Clywedog merger had not yet closed.
- Net loss narrowed to $6.1M in Q3 FY2026 from $14.6M in Q3 FY2025.
- R&D expense fell to $1.3M from $5.4M, driven by deprioritized legacy assets.
- Cash and equivalents dropped to $49.2M from $70.5M at year-end 2025.
- Self-tender repurchased 920,605 shares (~20.28%) for ~$6.1M in October 2026.
- Share premium reallocation of $103.2M moved to accumulated deficit in Q3.
Price data unavailable.
A pre-merger 10-Q showing sharply reduced losses and a $6.1M self-tender, ahead of the Clywedog combination that will define the company's pipeline.
Clinical-stage biotech pivoting to I&I/metabolic disease via the Clywedog merger; legacy Barinthus assets deprioritized.
Clywedog merger not yet closed, so no business combination accounting recorded; contingent consideration of $3.1M remains subject to milestone fair-value remeasurement.